Nagoya University · 의학
Fumiharu Ohka 교수의 연구실은 뇌신경계 종양, 특히 간질성 뇌종양인 간질성 뇌종양과 난치성 뇌종양의 치료 내성 메커니즘을 규명하는 데 초점을 맞추고 있습니다. 주로 MGMT 메틸화, glioma stem-like 세포, 혈뇌장벽 등 치료 저항성의 핵심 요인을 분석하며, 특히 IDH 유전자 상태에 따른 뇌종양의 분자적 기전과 새로운 치료 타겟을 탐색하고 있습니다. 또한 뇌종양의 생물학적 특성을 정밀하게 재현하는 옹호모델을 활용한 신약 탐색도 진행 중입니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Despite aggressive treatment including surgery, adjuvant TMZ-based chemotherapy, and radiotherapy, GBM still has a dismal prognosis: the median survival is 14.6 months from diagnosis. To date, many studies report several determinants of resistance to this aggressive therapy: (1) O(6)-methylguanine-DNA methyltransferase (MGMT), (2) the complexity o
Gliomas are the most frequently occurring primary brain tumor in the central nervous system of adults. Glioblastoma multiformes (GBMs, WHO grade 4) have a dismal prognosis despite the use of the alkylating agent, temozolomide (TMZ), and even low grade gliomas (LGGs, WHO grade 2) eventually transform to malignant secondary GBMs. Although GBM patients benefit from promoter hypermethylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) that is the main determinant of resistance to TMZ, rec
An organoid model for meningioma enabled us to elucidate the tumor biology of meningioma along with potent treatment targets for meningioma.
Gliomas are classified by combining histopathologic and molecular features, including isocitrate dehydrogenase (<i>IDH</i>) status. Although <i>IDH</i>-wild-type diffuse astrocytic glioma (DAG) shows a more aggressive phenotype than <i>IDH</i>-mutant type, lack of knowledge regarding relevant molecular drivers for this type of tumor has hindered the development of therapeutic agents. Here, we examined human <i>IDH</i>-wild-type DAGs and a glioma mouse model with a mosaic analysis with double mar
